MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UBS Downgrades Merck & Co. to Neutral from Buy, Adjusts Price Target to $76 from $98

12/13/2021 | 09:40am EDT


© MT Newswires 2021
All news about MERCK & CO., INC.
05/25Merck - European Commission Approves KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoa..
AQ
05/24Merck & Company Declares Quarterly Cash Dividend of $0.69 a Share, Payable July 8 to St..
MT
05/24Merck Announces Third-Quarter 2022 Dividend
BU
05/24Merck Declares Dividend for the Third Quarter of 2022, Payable on July 8, 2022
CI
05/24Merck's Keytruda Receives European Commission Approval for Breast Cancer
MT
05/24European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant..
BU
05/24Merck Announces European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherap..
CI
05/24Merck Gets EU Approval of Expanded Keytruda Use in Breast Cancer
DJ
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positiv..
MT
05/23Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) as Adjuvant Treatm..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 57 872 M - -
Net income 2022 15 235 M - -
Net Debt 2022 18 007 M - -
P/E ratio 2022 15,5x
Yield 2022 2,97%
Capitalization 237 B 237 B -
EV / Sales 2022 4,41x
EV / Sales 2023 4,35x
Nbr of Employees 67 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 93,75 $
Average target price 96,04 $
Spread / Average Target 2,45%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.22.33%237 075
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530